Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia.”

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

Results showed an unequal distributions of these clinical trials among rural and low-income populations.

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in future clinical trials.

Companies working in the retina space have announced that data from clinical trials will be shared at this year’s meeting in Fort Lauderdale, Florida.

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for broadening the dosing schedule to include every-4-week dosing across approved indications.

A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.

Phase I/II safety and efficacy study currently enrolling.

As part of its five-year strategic plan, Prevent Blindness has promoted five individuals to further the organization’s mission.

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

Congenital ectopia lentis is a rare ocular disease characterized by the dislocation or displacement of the lens.

Eyecyte-RPE is a suspension of human induced pluripotent stem cells derived from retinal pigment epithelial cells.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.

Nau will lead the company in a new phase of growth and innovation.

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).

A new study found that an artificial intelligence reading label system improves ophthalmologists' diagnostic accuracy for retinal diseases and could be valuable in future medical education.

Researchers introduce a multistage dual-branch network to improve accuracy and efficiency.

PYK-2101 is a focal hydrogel retinal sealant for use in patients undergoing surgery for a detached retina.

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

The company specializes in advanced modality antibody drugs.

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular edema.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 was set by the organization.

Good safety profile and “meaningful improvement” in vision in Leber congenital amaurosis patient.

Although it improved interdisciplinary communication, ongoing review and safety monitoring are necessary for successful clinical implementation.